Recursion Pharmaceuticals, Inc. (RXRX)
2.71
-0.01
(-0.37%)
USD |
NASDAQ |
Nov 20, 09:49
Recursion Pharmaceuticals Cash from Operations (Quarterly) : -77.41M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -77.41M |
| June 30, 2026 | -105.95M |
| March 31, 2026 | -81.10M |
| December 31, 2025 | -46.07M |
| September 30, 2025 | -117.36M |
| June 30, 2025 | -76.42M |
| March 31, 2025 | -131.96M |
| December 31, 2024 | -115.43M |
| September 30, 2024 | -59.22M |
| June 30, 2024 | -82.22M |
| March 31, 2024 | -102.30M |
| December 31, 2023 | -74.08M |
| September 30, 2023 | -72.92M |
| June 30, 2023 | -67.47M |
| Date | Value |
|---|---|
| March 31, 2023 | -73.32M |
| December 31, 2022 | -44.75M |
| September 30, 2022 | -54.54M |
| June 30, 2022 | -61.62M |
| March 31, 2022 | 77.39M |
| December 31, 2021 | -61.16M |
| September 30, 2021 | -33.05M |
| June 30, 2021 | -33.65M |
| March 31, 2021 | -30.76M |
| December 31, 2020 | 8.573M |
| September 30, 2020 | -19.46M |
| June 30, 2020 | -16.70M |
| March 31, 2020 | -17.82M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Absci Corp. | -29.47M |
| Editas Medicine, Inc. | -21.19M |
| Twist Bioscience Corp. | -0.173M |
| Beam Therapeutics, Inc. | -110.75M |
| AbbVie, Inc. | 7.606B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.407M |
| Cash from Financing (Quarterly) | 83.14M |
| Free Cash Flow | -314.48M |
| Free Cash Flow Per Share (Quarterly) | -0.1433 |
| Free Cash Flow to Equity (Quarterly) | -85.88M |
| Free Cash Flow to Firm (Quarterly) | -77.55M |
| Free Cash Flow Yield | -20.68% |